Current and future treatment options in osteoporosis.

Hdl Handle:
http://hdl.handle.net/10147/207160
Title:
Current and future treatment options in osteoporosis.
Authors:
Brewer, Linda; Williams, David; Moore, Alan
Affiliation:
General and Geriatric Medicine, Beaumont Hospital, Dublin, Ireland., lindabrewer@physicians.ie
Citation:
Eur J Clin Pharmacol. 2011 Apr;67(4):321-31. Epub 2011 Feb 16.
Journal:
European journal of clinical pharmacology
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207160
DOI:
10.1007/s00228-011-0999-2
PubMed ID:
21327420
Abstract:
PURPOSE: The incidence of osteoporosis-related fractures will increase substantially over the coming decades as the population ages globally. This has important economic and public health implications, contributing substantially to morbidity and excess mortality in this population. METHODS: When prescribing for older patients the effectiveness profile of drugs needs to be balanced against their tolerability in individual patients. RESULTS: Currently we have good anti-fracture data to support the use of many available anti-resorptive and anabolic drugs including bisphosphonates, strontium ranelate and recombinant human parathyroid hormone. We also have evidence to demonstrate the importance of calcium and vitamin D repletion in these patients. However, in recent years our understanding of normal bone physiology and the mechanisms underlying the development of osteoporosis has significantly advanced and this has led to the development of new therapies. Novel agents, particularly denosumab, but also inhibitors of cathepsin K and anabolic agents that act on Wnt signalling, will increase the therapeutic options for clinicians in the coming years. CONCLUSION: This review discusses the evidence supporting the use of currently available treatment options for osteoporosis and potential future advances in drug therapy. Particular consideration should be given when prescribing for certain older patients who have issues with compliance or tolerance and also in those with co-morbidities or levels of frailty that may restrict the choice of therapy. Understanding the evidence for the benefit and possible harm of osteoporosis treatments is critical to appropriate management of this patient population.
Language:
eng
MeSH:
Anabolic Agents/*therapeutic use; Bone Density Conservation Agents/*therapeutic use; Fractures, Bone/complications/*prevention & control; Humans; Models, Biological; Molecular Targeted Therapy; Osteoporosis/complications/*drug therapy; Risk Factors
ISSN:
1432-1041 (Electronic); 0031-6970 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorBrewer, Lindaen_GB
dc.contributor.authorWilliams, Daviden_GB
dc.contributor.authorMoore, Alanen_GB
dc.date.accessioned2012-02-01T10:00:43Z-
dc.date.available2012-02-01T10:00:43Z-
dc.date.issued2012-02-01T10:00:43Z-
dc.identifier.citationEur J Clin Pharmacol. 2011 Apr;67(4):321-31. Epub 2011 Feb 16.en_GB
dc.identifier.issn1432-1041 (Electronic)en_GB
dc.identifier.issn0031-6970 (Linking)en_GB
dc.identifier.pmid21327420en_GB
dc.identifier.doi10.1007/s00228-011-0999-2en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207160-
dc.description.abstractPURPOSE: The incidence of osteoporosis-related fractures will increase substantially over the coming decades as the population ages globally. This has important economic and public health implications, contributing substantially to morbidity and excess mortality in this population. METHODS: When prescribing for older patients the effectiveness profile of drugs needs to be balanced against their tolerability in individual patients. RESULTS: Currently we have good anti-fracture data to support the use of many available anti-resorptive and anabolic drugs including bisphosphonates, strontium ranelate and recombinant human parathyroid hormone. We also have evidence to demonstrate the importance of calcium and vitamin D repletion in these patients. However, in recent years our understanding of normal bone physiology and the mechanisms underlying the development of osteoporosis has significantly advanced and this has led to the development of new therapies. Novel agents, particularly denosumab, but also inhibitors of cathepsin K and anabolic agents that act on Wnt signalling, will increase the therapeutic options for clinicians in the coming years. CONCLUSION: This review discusses the evidence supporting the use of currently available treatment options for osteoporosis and potential future advances in drug therapy. Particular consideration should be given when prescribing for certain older patients who have issues with compliance or tolerance and also in those with co-morbidities or levels of frailty that may restrict the choice of therapy. Understanding the evidence for the benefit and possible harm of osteoporosis treatments is critical to appropriate management of this patient population.en_GB
dc.language.isoengen_GB
dc.subject.meshAnabolic Agents/*therapeutic useen_GB
dc.subject.meshBone Density Conservation Agents/*therapeutic useen_GB
dc.subject.meshFractures, Bone/complications/*prevention & controlen_GB
dc.subject.meshHumansen_GB
dc.subject.meshModels, Biologicalen_GB
dc.subject.meshMolecular Targeted Therapyen_GB
dc.subject.meshOsteoporosis/complications/*drug therapyen_GB
dc.subject.meshRisk Factorsen_GB
dc.titleCurrent and future treatment options in osteoporosis.en_GB
dc.contributor.departmentGeneral and Geriatric Medicine, Beaumont Hospital, Dublin, Ireland., lindabrewer@physicians.ieen_GB
dc.identifier.journalEuropean journal of clinical pharmacologyen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.